IDIQ for the purchase of consumables (multi-well plates) for use in Axion Biosystems Multielectrode Array systems

The U.S. Food and Drug Administration, through the Office of Acquisition and Grant Services within the Department of Health and Human Services, is conducting a market survey to gather information for a potential Indefinite Delivery, Indefinite Quantity (IDIQ) contract to procure specialized multi-well plates compatible with Axion Biosystems Multielectrode Array systems. This notice, identified by solicitation number 75F40126SSN133126, is explicitly marked as a sources-sought announcement and not a solicitation for proposals, meaning no contract will be awarded directly from this action. The IDIQ, if established, would include a base year from July 31, 2026, to July 30, 2027, with four option years extending through July 30, 2031. The plates are intended for use in drug safety and efficacy research, requiring newly manufactured products that support real-time, well-by-well electrophysiological signal monitoring, adjustable analog and digital filtering, temperature and electrical stimulation control, and automated detection of cardiac T-waves and neural network bursts, along with calculation of field potential duration, beat period, conduction velocity, depolarization, and spike amplitude. Respondents must provide detailed information including business name, bio, SAM Unique Entity ID, business address, website, and socioeconomic status such as Small Business, Veteran-Owned Small Business, Service-Disabled Veteran-Owned Small Business, HUBZone Small Business, Small Disadvantaged Business, Women-Owned Small Business, or Large Business. Manufacturers or authorized resellers must disclose the place of manufacture to evaluate compliance with the Buy American Act and Made in America requirements, and non-manufacturers must submit an OEM letterhead verifying their authorized reseller status. Estimated annual quantities are specified for certain configurations—50 boxes of five plates per year for M768-tMEA-96W, and 25 boxes of five plates per year for M768-tMEA-48W, M768-tMEA-48OPT—while quantities for other variants remain unspecified. All deliveries must be made within 30 days of order placement to the FDA’s Center for Drug Evaluation and Research in Silver Spring, Maryland. Responses are due by June 3, 2026, at 3:00 p.m. Central Time and must be submitted exclusively via email to Suzanne Martella at suzanne.martella@fda